4 pm EST, Tuesday, Jan 25th
Rob Allen (in lieu of CEO Anthony Davies) chaired the Superplenary session, complete with three fireside chats, from the Patient Perspective, the Pharma Perspective, and the Investor Perspective.
11 am EST, Wednesday Jan 26th
Katy Spink (in lieu of CEO Anthony Davies) chaired Overcoming the Commercial Roadblocks for Cell and Gene Therapy Success.
.png)
